First description of phenotypic profile and in vitro drug susceptibility of Cryptococcus spp yeast isolated from HIV-positive and HIV-negative patients in State of Mato Grosso;Primeira descrição da caracterização fenotípica e susceptibilidade in vitro a drogas de leveduras do gênero Cryptococcus spp isoladas de pacientes HIV positivos e negativos, Estado de Mato Grosso

Revista da Sociedade Brasileira de Medicina Tropical

Volumn 42, Issue 6, 2009, Pages 661-665

  Favalessa, Olivia Cometti ^a   Ribeiro, Luciano Correa ^b   Tadano, Tomoko ^b   Fontes, Cor Jesus Fernandes ^b   Dias, Flávio Basili ^a   Coelho, Bruno Pereira Albuquerque ^a   Hahn, Rosane Christine ^a,b  

^a UNIVERSIDADE FEDERAL DE MATO GROSSO   (Brazil)

^b HOSPITAL UNIVERSITÁRIO JÚLIO MÜLLER   (Brazil)

Author keywords

Antifungal drugs; Cryptococcus spp; HIV; Mato Grosso

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; VORICONAZOLE;

ARTICLE; BRAZIL; CONTROLLED STUDY; CRYPTOCOCCUS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DOSE RESPONSE; DRUG RESISTANCE; DRUG SENSITIVITY; FUNGUS IDENTIFICATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; NONHUMAN; PHENOTYPE;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PHENOTYPE; PROSPECTIVE STUDIES;

CRYPTOCOCCUS GATTII; FILOBASIDIELLA NEOFORMANS;

EID: 77949839417     PISSN: 00378682     EISSN: None     Source Type: Journal    
DOI: 10.1590/S0037-86822009000600010     Document Type: Article

References (32)

1. AB Biodisk. Etest Technical guide 4b: Antifungal susceptibility testing of yeasts. Piscataway: AB Biodisk, New Jersey, 1994.
2. Aller AI, Martin-Mzuelos E, Lozano F, Gomez-Mateos J, Steele-Moore L, Holloway WJ, Gutiérrez MJ, recio FJ, Espinel-Ingrof A. Correlation of Fluconazol MICs with Clinical Outcome in Cryptococcal infection. Antimicrobial Agents and Chemotherapy 44: 1544-1548, 2000.
3. Alves SH, Oliveira LT, Costa JM, Lubeck I, Casali AK, Vainstein MH. In vitro susceptibility to Antifungal Agents of Clinical and Environmental Cryptococcus neoformans isolated in Southern of Brazil. Revista do Instituto de Medicina Tropical de São Paulo 43: 267-270, 2001.
4. Ballesté R, Arteta Z, Barloco A, Mier C, Fernández N, Mousqués N, Xavier B, Cabrera MJ, Combol A, Gezuele E. Evaluación Del desempeño diagnóstico Del médio de difusión em Agar Etest para El estúdio de sensibilidad a los antifúngicos. Revista Medica Del Uruguay 22:128-135, 2006.
5. Calhoun DL, Roberts GD, Galgiani JN, Bennett JE, Feingold DS, Jorgensen J, Kobayashi GS, Shadomy S. Results of survey of antifungal susceptibility tests in the United States and interlaboratory comparison of broth dilution testing of flucytosine and amphotericin. Bangladesh Journal Clinical Microbiology 23:298-301, 1986.
6. Chandenier J, Adou-Bryan KD, Douchet C, Sar B, Kombila M, Swinne D, Thérizol-Ferly M, Buisson Y, Richard-Lenoble D. In vitro activity of amphotericin B, Fluconazol and Voriconazole against 162 Cryptococcus neoformans isolates. from Africa and Cambodia. European Journal Clinical Microbiology Infection Diseases 23: 506-508, 2004.
7. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, Ellis D, Marriott D, Pfeiffer T, Parr D, Byth K. Australasian Cryptococcal Study Group Epidemiology and Host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clinical Infectious Diseases 31: 499-508, 2000.
8. Chen SC, Sorrell TC. Antifungal agents: new drugs, old drugs. Medical Journal of Australia 187: 404-409, 2007. 9. Colombo AL, Barchiesi F, Mcgough DA, Rinald MG. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. Journal of Clinical Microbiology 33:535-540, 1995.
9. De Bedout C, Ordónez N, Gómez BL, Rodriguez MC, Arango M, Restrepo A, Castaneda. In vitro antifungal susceptibility of clinical isolates of Cryptococcus neoformans var. neoformans and Cryptococcus neoformans var. gattii. Revista Iberoamericana de Micologia 16:36-39, 1999.
10. Dismukes WE. Cryptococcal meningitis in patients with AIDS. Journal Infection Diseases 157:624.628, 1988.
11. Ellis DH, Pfeiffer TJ. Natural Habitat of Cryptococcus neoformans var. gattii. Journal of Clinical Microbiology 25:430-431, 1990.
12. Ellis DH, Pfeiffer TJ. Ecology, life cycle, and infectious propagule of Cryptococcus neoformans. Lancet 336: 923-925, 1990.
13. Fernandes OFL, Costa TR, Costa MR, Soares AJ, Pereira AJSC, Silva MR. Cryptococcus neoformans isolados de pacientes com AIDS. Revista da Sociedade Brasileira de Medicina Tropical 33: 75-78, 2000.
14. Fromtling RA, Bulmer GS. Distribution of Cryptococcus neoformans in a natural site. Infection and Immunity 31: 560-563, 1981.
15. Illnait-Zaragozi MT, Martínez GF, Curfs-Breuker I, Fernadez CM, Boekhout T, Meids JF. In vitro activity of the New Azole Isavuconazole (BAL4815) compared with six other Antifungal Agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrobial Agents and Chemotherrapy 52: 1580-1582, 2008.
16. Kobayashi CCBA, Souza LKH, Fernandes OFL, Brito SCA, Silva AC, Souza ED, Silva MRR. Characterization of Cryptococcus neoformans isolated from urban environmental sources in Goiânia, Goiás State, Brazil. Revista do Instituto Medicina Tropical São Paulo 47: 203-207, 2005.
17. Kwon-Chung KJ, Polacheck I, Bennett JE. Improved diagnostic Medium for Separation of Cryptococcus neoformans var. neoformans (Serotypes A and D) and Cryptococcus neoformans var. gattii (Serotypes B and C). Journal of Clinical Microbiology 15:535-537, 1982.
18. Lindenberg ASC, Chang MR, Paniago AMM, Lazéra MS, Moncada PMF, Bonfim GS, Nogueira AS,Wanke B. Clinical and Epidemiological features of 123 cases of cryptococcosis in Mato Grosso do Sul, Brazil. Revista do Instituto de Medicina Tropical 50: 75-78, 2008.
19. Lozano-Chiu MVL, Paetznick MA, Gannoum Rex JH. Detection of resistance to amphotericin B among Cryptococcus neoformans clinical isolates: performances of three different media assessed by using E-test and National Committee for Clinical Laboratory Standards M27-A methodology. Journal of Clinical Microbiology 36: 2817-2822, 1998.
20. Maxwell MJ, Messer SA, Hollis RJ, Dieckma DJ, Pfaller MA. Evaluation of Etest Method for Determining Voriconazole and Amphotericin B MICs for 162 Clinical Isolates of Cryptococcus neoformans. Journal of Clinical Microbiology 41: 97-99, 2003.
21. Ministério da Saúde. Dados e Pesquisa em DST e Aids. Coordenação do programa nacional de DST/Aids. Boletim Epidemiológico. AIDS/Ministério da Saúde. Brasília, 2002.
22. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS - 100 years after the discovery of Cryptococcus neoformans. Clinical Microbiology and Infection 8: 515-548, 1995.
23. Nguyen MH, Yu CY. In vitro comparative efficacy of vorconazole nd itrconzole against fluconazole-susceptible and resistant Cryptococcus neoformans isolates. Antimicrobial Agents Chemotherapy 42: 471-472, 1998.
24. Pappalardo MCSM, Melhem MSC. Cryptococcosis: A Review of the Brazilian Experience for the Disease. Revista do Instituto de Medicina Tropical 45:299-305, 2003.
25. Pedroso RS, Ferreira JC, Candido RC. In vitro susceptibility antifungal agents of environmental Cryptococcus spp, isoled in the city of Ribeirão Preto, São Paulo, Brazil. Memórias do Instituto Osvaldo Cruz 101: 239-243, 2006.
26. Powderly WG. Cryptococcal meningitis and AIDS. Clinical Infection Diseases 17:837-842, 1993.
27. Reolon A, Perez LRR, Mezzari A. Prevalência de Cryptococcus neoformans nos pombos urbanos da cidade de Porto Alegre, Rio Grande do Sul. Jornal Brasileiro de Patologia e Medicina Laboratorial 40: 293-298, 2004.
28. Rodriguez-Tudela JL, Berenguer Martinez-Suarez JJ, Sanchez R. Comparision of a Spectrophotometric Microdilution Method with RPMI-2% Glucose with the National Committee for Clinical Laboratory Standards Reference Macrodiluition Method M27-P for in vitro Susceptibility Testing of Amphotericin B, Flucytosine, and Fluconazol against Candida albicans. Antimicrobial and Chemotherapy 40: 1998-2003, 1996.
29. Saag MS, Graybill RJ, Larsen RA, Pappas PG, Perfect JR. Powderly WG, Sobel JD, Dismukes WE. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of American. Clinical Infection Diseases 30: 710-718, 2000.
30. Souza LKH, Fernandes OFL, Kobayashi CCBA, Passos XS, Costa CR, Lemos JA, Souza-Júnior AH, Silva MRR. Antifungal susceptibilities of clinical and environmental isolates of Cryptococcus neoformnas in Goiânia City, Goiás, Brazil. Revista do Instituo de Medicina Tropical de São Paulo 47: 253-256, 2005.
31. Sorrel TC, Ellis DH. Ecology of Cryptococcus neoformans. Revista Iberoamericana de Micologia 14:42-43, 1997.
32. Trilles L, Fernández-Torres B, Lazéra MS, Wanke B, Guarro J. In vitro Antifungal Susceptibility of Cryptococcus gattii. Journal of Clinical Microbiology 42: 4815-4817, 2004.